N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions

Cancer remains a leading cause of mortality in Japan, yet participation in conventional screening programs is low due to invasiveness, cost, and accessibility. Non-invasive, affordable, and accurate methods for early cancer detection in asymptomatic individuals are urgently needed. This opinion manu...

Full description

Saved in:
Bibliographic Details
Main Authors: Nobushige Nakajo, Hideyuki Hatakeyama, Masayo Morishita, Eric di Luccio
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/12/11/2546
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850145072860889088
author Nobushige Nakajo
Hideyuki Hatakeyama
Masayo Morishita
Eric di Luccio
author_facet Nobushige Nakajo
Hideyuki Hatakeyama
Masayo Morishita
Eric di Luccio
author_sort Nobushige Nakajo
collection DOAJ
description Cancer remains a leading cause of mortality in Japan, yet participation in conventional screening programs is low due to invasiveness, cost, and accessibility. Non-invasive, affordable, and accurate methods for early cancer detection in asymptomatic individuals are urgently needed. This opinion manuscript evaluates nematode cancer testing, a novel urine-based screening test using the nematode <i>Caenorhabditis elegans</i>, for its potential to improve early cancer detection rates, based on real-world data published in a Japanese journal. Nematode cancer testing leverages the nematode’s ability to detect cancer-associated volatile compounds in urine, offering a highly sensitive, non-invasive screening approach. We analyzed data from a nationwide survey of PET-equipped medical institutions in Japan, comparing cancer discovery rates between nematode cancer testing-triggered and standard PET screenings. In nematode cancer testing-triggered PET screenings, the cancer discovery rate was 2.96%, significantly higher than the 1.31% observed in standard PET screenings. The apparent positive predictive value (PPV) of nematode cancer testing was calculated at 2.09%; when adjusted for PET/CT sensitivity, the actual PPV increased to approximately 11.7%. This reflects a screening efficiency 14.6 times higher than the general population’s cancer incidence. These findings indicate that nematode cancer testing successfully detects cancer in high-risk individuals and may encourage participation in further diagnostic evaluations. The recently published nationwide survey of PET-equipped medical institutions in Japan highlights the good performance of nematode cancer testing in cancer detection. As an opinion-type manuscript based on real-world data from Japan, this paper shows that nematode cancer testing has substantial potential as a cost-effective, minimally invasive primary cancer screening tool for asymptomatic populations. By enhancing early detection rates and screening efficiency, it addresses the limitations of traditional screening methods. Implementing nematode cancer testing could lead to improved cancer outcomes, particularly in populations with low participation in standard screening programs and resource-limited settings.
format Article
id doaj-art-b6f154a942f8457aaa8043b24d1abbb0
institution OA Journals
issn 2227-9059
language English
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-b6f154a942f8457aaa8043b24d1abbb02025-08-20T02:28:11ZengMDPI AGBiomedicines2227-90592024-11-011211254610.3390/biomedicines12112546N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical InstitutionsNobushige Nakajo0Hideyuki Hatakeyama1Masayo Morishita2Eric di Luccio3Graduate School of Systems Life Sciences, Kyushu University, 744 motooka, Nishi-ku, Fukuoka 819-0395, JapanHirotsu Bio Science Inc., 22F The New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, JapanHirotsu Bio Science Inc., 22F The New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, JapanHirotsu Bio Science Inc., 22F The New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, JapanCancer remains a leading cause of mortality in Japan, yet participation in conventional screening programs is low due to invasiveness, cost, and accessibility. Non-invasive, affordable, and accurate methods for early cancer detection in asymptomatic individuals are urgently needed. This opinion manuscript evaluates nematode cancer testing, a novel urine-based screening test using the nematode <i>Caenorhabditis elegans</i>, for its potential to improve early cancer detection rates, based on real-world data published in a Japanese journal. Nematode cancer testing leverages the nematode’s ability to detect cancer-associated volatile compounds in urine, offering a highly sensitive, non-invasive screening approach. We analyzed data from a nationwide survey of PET-equipped medical institutions in Japan, comparing cancer discovery rates between nematode cancer testing-triggered and standard PET screenings. In nematode cancer testing-triggered PET screenings, the cancer discovery rate was 2.96%, significantly higher than the 1.31% observed in standard PET screenings. The apparent positive predictive value (PPV) of nematode cancer testing was calculated at 2.09%; when adjusted for PET/CT sensitivity, the actual PPV increased to approximately 11.7%. This reflects a screening efficiency 14.6 times higher than the general population’s cancer incidence. These findings indicate that nematode cancer testing successfully detects cancer in high-risk individuals and may encourage participation in further diagnostic evaluations. The recently published nationwide survey of PET-equipped medical institutions in Japan highlights the good performance of nematode cancer testing in cancer detection. As an opinion-type manuscript based on real-world data from Japan, this paper shows that nematode cancer testing has substantial potential as a cost-effective, minimally invasive primary cancer screening tool for asymptomatic populations. By enhancing early detection rates and screening efficiency, it addresses the limitations of traditional screening methods. Implementing nematode cancer testing could lead to improved cancer outcomes, particularly in populations with low participation in standard screening programs and resource-limited settings.https://www.mdpi.com/2227-9059/12/11/2546N-NOSEurine-based cancer screening<i>Caenorhabditis elegans</i>early cancer detectionPET/CTreal-world data
spellingShingle Nobushige Nakajo
Hideyuki Hatakeyama
Masayo Morishita
Eric di Luccio
N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
Biomedicines
N-NOSE
urine-based cancer screening
<i>Caenorhabditis elegans</i>
early cancer detection
PET/CT
real-world data
title N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
title_full N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
title_fullStr N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
title_full_unstemmed N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
title_short N-NOSE Proves Effective for Early Cancer Detection: Real-World Data from Third-Party Medical Institutions
title_sort n nose proves effective for early cancer detection real world data from third party medical institutions
topic N-NOSE
urine-based cancer screening
<i>Caenorhabditis elegans</i>
early cancer detection
PET/CT
real-world data
url https://www.mdpi.com/2227-9059/12/11/2546
work_keys_str_mv AT nobushigenakajo nnoseproveseffectiveforearlycancerdetectionrealworlddatafromthirdpartymedicalinstitutions
AT hideyukihatakeyama nnoseproveseffectiveforearlycancerdetectionrealworlddatafromthirdpartymedicalinstitutions
AT masayomorishita nnoseproveseffectiveforearlycancerdetectionrealworlddatafromthirdpartymedicalinstitutions
AT ericdiluccio nnoseproveseffectiveforearlycancerdetectionrealworlddatafromthirdpartymedicalinstitutions